Rechallenging taxanes in recurrent breast cancer in patients treated with (neo-) adjuvant taxane-based therapy.
X. Guo
No relevant relationships to disclose
S. Loibl
No relevant relationships to disclose
M. Untch
No relevant relationships to disclose
V. Möbus
No relevant relationships to disclose
K. Schwedler
No relevant relationships to disclose
P. A. Fasching
Consultant or Advisory Role - Novartis
Honoraria - AstraZeneca; Novartis; Pfizer
J. Barinoff
No relevant relationships to disclose
F. Holms
No relevant relationships to disclose
C. Thomssen
Honoraria - Bristol-Myers Squibb; Sanofi
Research Funding - Bristol-Myers Squibb; Sanofi
Other Remuneration - Sanofi
D. M. Zahm
No relevant relationships to disclose
R. Kreienberg
Consultant or Advisory Role - AstraZeneca; Novartis
Honoraria - Amgen; Cephalon; GlaxoSmithKline
M. Hauschild
No relevant relationships to disclose
H. Eidtmann
No relevant relationships to disclose
S. Tauchert
No relevant relationships to disclose
K. Mehta
No relevant relationships to disclose
G. Von Minckwitz
No relevant relationships to disclose